Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.75 |
| ▸ | PAM | P19021 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505232 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Hexane SCHEMBL17350930 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL13280125 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL8538 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL5204092 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Hexane SCHEMBL3152849 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL5533 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL11567674 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL8326852 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Heptane SCHEMBL16027604 | 1.00 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-113307772-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-106257976-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-09-11 | — | — | US | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2881392-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| US-5017724-A | Antihypoxic, CNS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0267024-B1 | HYDROFLUORENE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4920103-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0267024-A2 | Hydrofluorene derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
| EP-0262904-A2 | Modifications of mycinose and 3-0-demethylmycinose in tylosintype macrolides | ELI LILLY AND COMPANY (US) | 1988-04-06 | — | — | EP | disclosed |
| EP-0262903-A2 | New acyl derivatives of 20-modified tylosin and desmycosin compounds | ELI LILLY AND COMPANY (US) | 1988-04-06 | — | — | EP | disclosed |
| EP-0116495-A1 | Androstene-17-dithioketals | E.R. Squibb & Sons, Inc. (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4427592-A | Androstene-17-dithioketals | E. R. SQUIBB & SONS, INC. (US) | 1984-01-24 | — | — | US | disclosed |
| US-4060691-A | 7-{3-Hydroxy-2-[4-hydroxy-4-(lower alkyl)-trans-1-octen-1-yl]-5-oxocyclopent-1-yl}heptanoic acids and esters | G. D. SEARLE & CO. (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | DGKA 2104/4885PAM 2194/4885TSHR 396/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | DGKA 2106/4885PAM 2255/4885TSHR 430/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | DGKA 2101/4885PAM 2100/4885TSHR 405/4885 |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | DGKA 2104/4885PAM 2194/4885TSHR 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.